The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.
 
Jason Westin
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb/Celgene/Juno; Genentech/Roche; Iksuda Therapeutics; Janssen Scientific Affairs; Kite/Gilead; Merck; Monte Rosa Therapeutics; MorphoSys/Incyte; Novartis; Seagen
Research Funding - ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb; Genentech; Janssen; Kite/Gilead; MorphoSys/Incyte; Novartis
 
Olalekan O. Oluwole
Honoraria - Gilead Sciences; Pfizer
Consulting or Advisory Role - AbbVie; ADC Therapeutics; Curio Science; Epizyme; Gilead Sciences; Janssen; Kite, a Gilead Company; Nektar; Novartis; Pfizer; Syncopation Life Sciences; TG Therapeutics
Research Funding - Allogene Therapeutics (Inst); Daiichi Sankyo Pharmaceutical (Inst); Kite, a Gilead Company (Inst); Pfizer (Inst)
 
Marie José Kersten
Honoraria - Adicet Bio; Bristol-Myers Squibb/Celgene; Kite, a Gilead Company; Miltenyi Biotec; Novartis; Roche
Consulting or Advisory Role - Adicet Bio; Bristol-Myers Squibb/Celgene; Kite, a Gilead Company; Miltenyi Biotec; Novartis; Roche
Research Funding - Celgene; Kite, a Gilead Company; Roche; Takeda
Travel, Accommodations, Expenses - Kite, a Gilead Company; Miltenyi Biotec; Novartis; Roche
 
David Bernard Miklos
Honoraria - fosun Kite Biotechnology; Janssen
Consulting or Advisory Role - Adaptive Biotechnologies; Allogene Therapeutics; Caribou Biosciences; Janssen; Kite, a Gilead company
Research Funding - Adaptive Biotechnologies; Adicet Bio; Alimera Sciences; Kite, a Gilead company; Novartis; Pharmacyclics; Precision Biosciences; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Patent held with Pharmacyclics supporting Ibrutinib for cGVHD (no royalty claim)
 
Miguel-Angel Perales
Stock and Other Ownership Interests - NexImmune
Honoraria - MorphoSys
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Cidara Therapeutics; Incyte; Kite/Gilead; Medigene; Merck; MolMed; Nektar; NexImmune; Novartis; Omeros; Servier/Pfizer; Vor Biopharma
Research Funding - Incyte (Inst); Kite, a Gilead company (Inst); Miltenyi Biotec (Inst); Nektar (Inst); Novartis (Inst)
 
Armin Ghobadi
Consulting or Advisory Role - Amgen; Atara Biotherapeutics; Celgene; CovACE Nanotechnology; crispr therapeutics; EUSA Pharma; Kite/Gilead; WUGEN, Inc.
Research Funding - Amgen; Kite, a Gilead company
 
Aaron Rapoport
No Relationships to Disclose
 
Anna Sureda
Honoraria - Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Janssen-Cilag; Merck Sharp & Dohme; Novartis; Roche; Sanofi; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Novartis; Takeda
Speakers' Bureau - Takeda
Travel, Accommodations, Expenses - Kite/Gilead
Other Relationship - Celgene; Gilead Sciences; Roche; Sanofi; Takeda
 
Caron Alyce Jacobson
Honoraria - Abintus Bio; Bluebird Bio; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Epizyme; ImmPACT-Bio; Instil Bio; Ipsen; Kite/Gilead; Lonza; Novartis
Consulting or Advisory Role - Abintus Bio; Bluebird Bio; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Epizyme; ImmPACT-Bio; Instil Bio; Ipsen; Kite/Gilead; Lonza; Novartis
Research Funding - Kite, a Gilead company; Pfizer
 
Umar Farooq
Honoraria - Caribou Biosciences; Kite, a Gilead company; Morphosys
Research Funding - Checkmate Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Tom van Meerten
Honoraria - Kite/Gilead
Consulting or Advisory Role - Janssen
Research Funding - Celgene (Inst); Genentech (Inst)
 
Matthew L. Ulrickson
Consulting or Advisory Role - Gilead Sciences; Stemline Therapeutics
 
Mahmoud Elsawy
Honoraria - Bristol-Myers Squibb; Janssen; Kite, a Gilead Company; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Kite, a Gilead Company; Novartis; Pfizer
 
Lori A. Leslie
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Epizyme; Johnson & Johnson/Janssen; Kite, a Gilead Company; Lilly O.; Merck; Pharmacyclics; Seagen; TG Therapeutics
Speakers' Bureau - Abbvie; AstraZeneca; BeiGene; Celgene/Bristol-Myers Squibb; Epizyme; Janssen; Kite, a Gilead Company; Lilly O.; Pharmacyclics; Seagen; TG Therapeutics
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; BeiGene; Celgene/Bristol-Myers Squibb; Epizyme; Janssen; Kite, a Gilead Company; Lilly O.; Pharmacyclics; Seagen; TG Therapeutics
 
Sridhar Chaganti
Honoraria - Adicet Bio; Atara Biotherapeutics; Incyte; Kite, a Gilead Company; Orion
Consulting or Advisory Role - Adicet Bio; Atara Biotherapeutics; Incyte; Kite, a Gilead Company; Orion
Speakers' Bureau - Hartley Taylor Medical; Incyte; Kite, a Gilead Company; Takeda
Research Funding - Atara Biotherapeutics; Autolus; Genmab; Janssen; Kite, a Gilead Company; MorphoSys; Novartis
Travel, Accommodations, Expenses - Kite, a Gilead Company; Takeda
 
Michael Dickinson
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Gilead Sciences; Janssen; MSD; Novartis; Roche
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Genmab; Gilead Sciences; Janssen; Novartis; Roche (I)
Research Funding - Abbvie (Inst); Celgene (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche
 
Yin Yang
Employment - Kite, a Gilead Company
 
Marco Andreas Schupp
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Christina Ann To
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Frederick L. Locke
Consulting or Advisory Role - A2 Biotherapeutics; Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Caribou Biosciences; Celgene; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Miltenyi Biotec; Novartis; Sana Biotechnology; Takeda; Takeda; Umoja Biopharma; Umoja Biopharma
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Kite, a Gilead company